US · NTLA · BIOTECHNOLOGY
Intellia Therapeutics, Inc. (NTLA) intrinsic value and stock valuation
$10.00as of 2026-11-21 · Mkt cap 1.23B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Intellia Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values NTLA with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from NTLA’s statements →
Intellia Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2014–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Spyre Therapeutics, Inc. (SYRE) $93.47
- Immunome, Inc. (IMNM) $15.69
- Pharvaris N.V. (PHVS) $31.28
- BioCryst Pharmaceuticals, Inc. (BCRX) $7.22
- Biohaven Ltd. (BHVN) $12.39
- Zenas BioPharma, Inc. (ZBIO) $23.85
- Stoke Therapeutics, Inc. (STOK) $26.81
- Zymeworks Inc. (ZYME) $26.14
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M |
| Operating income | -$-440.99M | -$-534.26M | -$-515.29M | -$-458.16M | -$-267.85M |
| Net income | -$-412.69M | -$-519.02M | -$-481.19M | -$-474.19M | -$-267.89M |
| EPSd | -$-3.81M | -$-5.25M | -$-5.42M | -$-6.16M | -$-3.78M |
| Operating cash flow | -$-348.88M | -$-348.88M | -$-394.09M | -$-333.29M | -$-225.03M |
| Capital expenditure | -$-5.78M | -$-5.78M | -$-13.98M | -$-58.39M | -$-12.76M |
| Free cash flow | -$-354.66M | -$-354.66M | -$-408.07M | -$-391.68M | -$-237.79M |
| Total assets | $842.1M | $1.19B | $1.3B | $1.52B | $1.29B |
| Total debt | $93.3M | $210.2M | $115.4M | $130.7M | $74M |
| Net debt | -$-62.13M | $21M | -$-111.4M | -$-392.8M | -$-49.38M |
| Total equity | $671.4M | $872M | $1.05B | $1.24B | $1.04B |
| Cash and short-term investments | $449.9M | $601.5M | $912.2M | $1.19B | $748.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M |
| Cost of revenue | $15.9M | $10.3M | $8.98M | $7.57M | $6.89M |
| Gross profit | $51.8M | $47.6M | $27.3M | $44.6M | $26.2M |
| Research and development expenses | $388.9M | $466.3M | $435.1M | $420M | $229.8M |
| Selling, general and administrative expenses | $119.8M | $125.8M | $116.5M | $90.3M | $71.1M |
| Other expenses | -$-15.92M | -$-10.29M | -$-8.98M | -$-7.57M | -$-6.89M |
| Operating expenses | $492.7M | $581.9M | $542.6M | $502.7M | $294M |
| Cost and expenses | $508.7M | $592.1M | $551.6M | $510.3M | $300.9M |
| Interest income | $29.2M | $47.8M | $49.8M | $8.54M | $1.28M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $15.9M | $10.3M | $8.98M | $7.57M | $6.89M |
| Ebitda | -$-396.77M | -$-508.74M | -$-472.22M | -$-466.61M | -$-261M |
| Operating income | -$-440.99M | -$-534.26M | -$-515.29M | -$-458.16M | -$-267.85M |
| Total other income/expenses, net | $28.3M | $15.2M | $34.1M | -$-16.02M | -$-40K |
| Income before tax | -$-412.69M | -$-519.02M | -$-481.19M | -$-474.19M | -$-267.89M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-412.69M | -$-519.02M | -$-481.19M | -$-474.19M | -$-267.89M |
| Weighted average shares outstanding | $108.4M | $98.9M | $88.8M | $77M | $70.9M |
| Weighted average diluted shares outstanding | $108.4M | $98.9M | $88.8M | $77M | $70.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $449.9M | $601.5M | $912.2M | $1.19B | $748.7M |
| Net receivables | $9.47M | $8.52M | $36.5M | $3.77M | $2.03M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $527.7M | $639.9M | $998.3M | $1.22B | $769.3M |
| Property, plant and equipment, net | $123.6M | $246.7M | $148.1M | $161M | $100.1M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $35.5M | $44.3M | $154.5M | $142.3M | $425.1M |
| Total non-current assets | $314.4M | $551.2M | $302.7M | $303.3M | $525.2M |
| Total assets | $842.1M | $1.19B | $1.3B | $1.52B | $1.29B |
| Accounts payable | $20.3M | $14.6M | $7.45M | $5.15M | $9.65M |
| Short-term debt | $26.5M | $20.3M | $18.6M | $16.7M | $9.11M |
| Deferred revenue | $7.29M | $20.7M | $22.1M | $43.8M | $63.8M |
| Total current liabilities | $103.9M | $110.9M | $115.2M | $126.6M | $125.8M |
| Long-term debt | $66.9M | $190M | $96.8M | $114M | $64.9M |
| Deferred revenue, non-current | $0.00 | $18.3M | $38.9M | $19.9M | $63.5M |
| Total non-current liabilities | $66.9M | $208.2M | $135.6M | $158M | $128.4M |
| Capital lease obligations | $26.5M | $210.2M | $115.4M | $130.7M | $74M |
| Total liabilities | $170.7M | $319.1M | $250.8M | $284.5M | $254.2M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-2.59B | -$-2.18B | -$-1.66B | -$-1.18B | -$-703M |
| Accumulated other comprehensive income (loss) | $1.03M | $600K | -$-2.26M | -$-7.46M | -$-2.63M |
| Total equity | $671.4M | $872M | $1.05B | $1.24B | $1.04B |
| Total investments | $330M | $456.6M | $840M | $811.4M | $1.05B |
| Total debt | $93.3M | $210.2M | $115.4M | $130.7M | $74M |
| Net debt | -$-62.13M | $21M | -$-111.4M | -$-392.8M | -$-49.38M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-519.02M | -$-519.02M | -$-481.19M | -$-474.19M | -$-267.89M |
| Depreciation and amortization | $10.3M | $10.3M | $8.98M | $7.57M | $6.89M |
| Stock-based compensation | $154.3M | $154.3M | $134.1M | $91.4M | $47M |
| Change in working capital | -$-73.75M | $11.9M | -$-52.45M | -$-53.87M | -$-22.9M |
| Accounts receivable | -$-950K | $27.9M | -$-32.69M | -$-1.74M | $100K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $7.82M |
| Accounts payable | $5.99M | $6.8M | $2.52M | -$-4.58M | $530K |
| Net cash provided by operating activities | -$-348.88M | -$-348.88M | -$-394.09M | -$-333.29M | -$-225.03M |
| Investments in property, plant and equipment | -$-5.78M | -$-5.78M | -$-13.98M | -$-58.39M | -$-12.76M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-44.68M | -$-3M |
| Net cash used for investing activities | $125.6M | $125.6M | -$-31.35M | $160.3M | -$-550.78M |
| Common stock issued | $131.5M | $176.9M | $119.8M | $565.8M | $693.6M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $185.8M | $185.8M | $130.3M | $583M | $736.7M |
| Net change in cash | -$-37.57M | -$-37.57M | -$-295.11M | $410M | -$-39.12M |
| Cash at end of period | $202.8M | $202.8M | $240.4M | $535.5M | $125.5M |
| Operating cash flow | -$-348.88M | -$-348.88M | -$-394.09M | -$-333.29M | -$-225.03M |
| Capital expenditure | -$-5.78M | -$-5.78M | -$-13.98M | -$-58.39M | -$-12.76M |
| Free cash flow | -$-354.66M | -$-354.66M | -$-408.07M | -$-391.68M | -$-237.79M |
Line items
Line items
Line items
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
- CEO
- John Leonard
- Employees
- 377
- Beta
- 1.77
Explore
Frequently asked questions
What is the intrinsic value of Intellia Therapeutics, Inc. (NTLA)?
Intellia Therapeutics, Inc. (NTLA) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NTLA undervalued?
NTLA trades at a price of $10.00 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.